Answers are grounded in this paper and cite their sources.
Our data provides valuable baseline information regarding the TGF-β pathway in pancreatic cancer, which can be utilized in targeted therapy clinical trials. High TGF-β1 plasma level, SMAD4 SNP or TGF-βR2/SMAD4 tumor protein expression may suggest a dependence on this pathway in patients with advanced pancreatic cancer.
No takes yet. Share an insight, caveat, or question.
Javle et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: